Alex Goldberg

Halozyme Therapeutics, Inc. (NASDAQ:HALO) and Micron Technology Inc. (NASDAQ:MU) Added to Equity Profile Report's NASDAQ Active Stock Watch List.

 
Repost This

Wilmington, DE -- (SBWIRE) -- 02/15/2014 -- Equity Profile Report expands its NASDAQ Active Stock Weekly Watch List adding Halozyme Therapeutics, Inc. (NASDAQ:HALO) and Micron Technology Inc. (NASDAQ:MU).

Halozyme Therapeutics, Inc. (NASDAQ:HALO) a biopharmaceutical company that engages in the research, development, and commercialization of human enzymes closed down in its previous session (-0.13%) on 887,528 shares traded. Halozyme Therapeutics, Inc. (NASDAQ:HALO) is currently down (-17.66%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List.

Click Here to find out what other Investors are saying about Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Micron Technology Inc. (NASDAQ:MU) a company that together with its subsidiaries, manufactures and markets semiconductor solutions worldwide closed up in its previous session (+0.68%) on 32,455,457 shares traded as Micron's Name Emerges in Cisco Memory Flap. Micron Technology Inc. (NASDAQ:MU) is currently up (+231.15%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List.

Click Here to find out what other Investors are saying about Micron Technology Inc. (NASDAQ:MU)

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.Equityprofilereport.com

Disclosure: Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com